John C. Fanaras, BSc

John C. Fanaras is a director of Jupiter Biomedical Research, Inc. and a highly experienced pharmaceutical services executive whose career has been centered on scientific testing, laboratory operations, toxicology, analytical chemistry, microbiology, regulatory support, and the practical infrastructure required to advance pharmaceutical and biotechnology development.

Mr. Fanaras is the co-founder and President of Nucro-Technics, one of Canada’s largest privately owned pharmaceutical contract support organizations. Under his leadership, Nucro-Technics has grown into a major scientific services company providing toxicology, genetic toxicology, biomarkers, bioanalytical testing, analytical chemistry, microbiology, and regulatory affairs consulting to pharmaceutical and biotechnology clients throughout the world. The company serves more than 400 companies globally, including 10 of the largest pharmaceutical companies, and employs more than 160 scientists.

His background is especially important to Jupiter Biomedical Research because JBR’s scientific programs require more than promising therapeutic concepts. They require disciplined preclinical planning, toxicology support, analytical validation, regulatory readiness, and the ability to understand how early-stage drug candidates must be evaluated before they can move toward formal development pathways. Mr. Fanaras brings decades of direct experience in the laboratory and regulatory environment that supports that process.

For more than four decades, Mr. Fanaras has been involved in all aspects of operational, investment, and management decisions for Nucro-Technics. That experience gives him a practical understanding of how pharmaceutical development programs are supported from the scientific services side — including study design, quality systems, compliance requirements, laboratory execution, client coordination, and regulatory documentation.

Nucro-Technics operates in a highly regulated environment and is inspected regularly for compliance with current Good Manufacturing Practices by both the United States Food and Drug Administration and Health Canada. The company is also in compliance with Good Laboratory Practice standards under the OECD Guidelines through the Standards Council of Canada. This regulatory and quality-control background is directly relevant to JBR as the Company works to advance biomedical research in a manner consistent with pharmaceutical industry expectations.

Together with Dr. David Vaughan, Mr. Fanaras forms an important part of JBR’s in-house scientific team. Dr. Vaughan brings extensive drug-development, clinical, regulatory, and CMC experience, while Mr. Fanaras contributes deep expertise in pharmaceutical laboratory operations, toxicology, analytical testing, microbiology, and regulated scientific services. Their combined experience strengthens JBR’s ability to evaluate scientific opportunities, plan development programs, assess preclinical needs, and communicate effectively with outside laboratories, consultants, regulators, and potential strategic partners.

Mr. Fanaras holds a Bachelor of Science degree in Microbiology. His scientific training, combined with decades of operational leadership in pharmaceutical contract research and testing, gives him a strong foundation for contributing to JBR’s biomedical development strategy.

In addition to his scientific and business career, Mr. Fanaras has maintained a longstanding commitment to community service and civic leadership. He has served as President and Chairman of the Board of the Hellenic Home for the Aged Inc., which provides 24-hour nursing care for 128 seniors, and as Chairman of the Board of Directors of the Hellenic Heritage Foundation. He has also served as a Board Director of the Scarborough Chamber of Commerce, Centennial College of Applied Arts and Technology, West Park Hospital, and the Association of Canadian Community Colleges.

At Jupiter Biomedical Research, Mr. Fanaras contributes scientific judgment, laboratory-development experience, regulatory awareness, and operational discipline. His career reflects the kind of practical pharmaceutical expertise that is essential to moving biomedical concepts from early promise toward credible development.